Rigel Pharmaceuticals (RIGL)
Market Price (11/1/2026): $0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
Rigel Pharmaceuticals (RIGL)
Market Price (11/1/2026): $0Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 34%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 30%, FCF Yield is 8.3% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.8, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -23% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 107% Key risksRIGL key risks include [1] intense commercial competition from larger, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 34%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 30%, FCF Yield is 8.3% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.8, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -23% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 107% |
| Key risksRIGL key risks include [1] intense commercial competition from larger, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Rigel Pharmaceuticals (RIGL) stock has gained about 40% since 7/31/2026 because of the following key factors:
1. Strong Q2 2026 Financial Performance Exceeding Expectations.
Rigel Pharmaceuticals reported robust financial results for its fiscal Q2 2026, which ended June 30, 2026, significantly surpassing analyst estimates. On August 4, 2026, the company announced earnings per share (EPS) of $0.88, considerably exceeding the consensus estimate of $0.09 by $0.79. Additionally, quarterly revenue reached $78.70 million, outperforming analyst expectations of $55.27 million. This strong performance, which also marked record net product sales, contributed to investor confidence and stock appreciation.
2. Expansion of Commercial Portfolio with VEPPANU™ Launch.
In fiscal Q2 2026, Rigel expanded its commercial product portfolio by in-licensing VEPPANU™ (vepdegestrant), the first and only FDA-approved PROTAC (PROteolysis TArgeting Chimera) for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. Rigel announced the commercial availability of VEPPANU™ in the U.S. was expected in mid-August 2026. This strategic move was highlighted as a further expansion of Rigel's commercial business in hematology and oncology.
Show more
Rigel Pharmaceuticals (RIGL) stock has gained about 40% since 7/31/2026 because of the following key factors:
1. Strong Q2 2026 Financial Performance Exceeding Expectations.
Rigel Pharmaceuticals reported robust financial results for its fiscal Q2 2026, which ended June 30, 2026, significantly surpassing analyst estimates. On August 4, 2026, the company announced earnings per share (EPS) of $0.88, considerably exceeding the consensus estimate of $0.09 by $0.79. Additionally, quarterly revenue reached $78.70 million, outperforming analyst expectations of $55.27 million. This strong performance, which also marked record net product sales, contributed to investor confidence and stock appreciation.
2. Expansion of Commercial Portfolio with VEPPANU™ Launch.
In fiscal Q2 2026, Rigel expanded its commercial product portfolio by in-licensing VEPPANU™ (vepdegestrant), the first and only FDA-approved PROTAC (PROteolysis TArgeting Chimera) for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. Rigel announced the commercial availability of VEPPANU™ in the U.S. was expected in mid-August 2026. This strategic move was highlighted as a further expansion of Rigel's commercial business in hematology and oncology.
3. Upgraded Full-Year 2026 Financial Guidance.
Following the strong Q2 2026 results and the addition of VEPPANU™ to its portfolio, Rigel Pharmaceuticals raised its full-year 2026 financial outlook. The company increased its total revenue guidance to approximately $285 million to $295 million, an upward revision from the previous range of $275 million to $290 million. Net product sales guidance was also increased to approximately $255 million to $265 million. This updated positive outlook signaled continued growth to the market.
4. Positive Analyst Upgrades and Increased Price Targets.
During the specified period, several financial analysts reiterated or upgraded their ratings for Rigel Pharmaceuticals and increased their price targets. For example, HC Wainwright reaffirmed a "buy" rating and raised its price target to $85.00 on October 19, 2026. Weiss Ratings upgraded Rigel from a "buy (b-)" to a "buy (b)" on October 8, 2026. Citigroup also reiterated a "buy" rating on August 6, 2026. The average analyst price target for the stock rose, reflecting improved market sentiment.
5. Promising Clinical Data Presentation for GAVRETO®.
Rigel Pharmaceuticals presented new data for GAVRETO® (pralsetinib) across RET fusion-positive cancers at the ESMO Congress 2026 on October 19, 2026. The oral and poster presentations highlighted clinically meaningful activity of GAVRETO®, including a 53% overall response rate in pooled analysis and strong response rates in specific cancer types like thyroid cancer (81.3%) and first-line NSCLC (65.5% versus 41.6% for standard of care). Positive clinical developments often fuel investor interest and contribute to stock gains in the biotechnology sector.
Show less
Stock Movement Drivers
Fundamental Drivers
The 39.4% change in RIGL stock from 7/31/2026 to 10/31/2026 was primarily driven by a 58.8% change in the company's P/E Multiple.| (LTM values as of) | 7312026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 36.81 | 51.31 | 39.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 300 | 277 | -7.7% |
| Net Income Margin (%) | 121.5% | 116.3% | -4.3% |
| P/E Multiple | 1.9 | 3.0 | 58.8% |
| Shares Outstanding (Mil) | 18 | 19 | -0.7% |
| Cumulative Contribution | 39.4% |
Market Drivers
7/31/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| RIGL | 39.4% | |
| Market (SPY) | 1.2% | 26.4% |
| Sector (XLV) | 13.7% | 49.9% |
Fundamental Drivers
The 77.5% change in RIGL stock from 4/30/2026 to 10/31/2026 was primarily driven by a 106.1% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.90 | 51.31 | 77.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 294 | 277 | -5.9% |
| Net Income Margin (%) | 124.7% | 116.3% | -6.7% |
| P/E Multiple | 1.4 | 3.0 | 106.1% |
| Shares Outstanding (Mil) | 18 | 19 | -1.8% |
| Cumulative Contribution | 77.5% |
Market Drivers
4/30/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| RIGL | 77.5% | |
| Market (SPY) | 5.4% | 13.1% |
| Sector (XLV) | 27.2% | 40.4% |
Fundamental Drivers
The 62.5% change in RIGL stock from 10/31/2025 to 10/31/2026 was primarily driven by a 218.5% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.58 | 51.31 | 62.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 268 | 277 | 3.3% |
| Net Income Margin (%) | 36.5% | 116.3% | 218.5% |
| P/E Multiple | 5.8 | 3.0 | -48.8% |
| Shares Outstanding (Mil) | 18 | 19 | -3.5% |
| Cumulative Contribution | 62.5% |
Market Drivers
10/31/2025 to 10/31/2026| Return | Correlation | |
|---|---|---|
| RIGL | 62.5% | |
| Market (SPY) | 11.7% | 17.9% |
| Sector (XLV) | 29.8% | 34.4% |
Fundamental Drivers
The 535.6% change in RIGL stock from 10/31/2023 to 10/31/2026 was primarily driven by a 210.7% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.07 | 51.31 | 535.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 127 | 277 | 118.6% |
| P/S Multiple | 1.1 | 3.4 | 210.7% |
| Shares Outstanding (Mil) | 17 | 19 | -6.4% |
| Cumulative Contribution | 535.6% |
Market Drivers
10/31/2023 to 10/31/2026| Return | Correlation | |
|---|---|---|
| RIGL | 535.6% | |
| Market (SPY) | 86.9% | 25.1% |
| Sector (XLV) | 55.5% | 27.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RIGL Return | -24% | -43% | -3% | 16% | 155% | 20% | 47% |
| Peers Return | -18% | -17% | -28% | -26% | 199% | -42% | -37% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| RIGL Win Rate | 33% | 33% | 42% | 42% | 58% | 60% | |
| Peers Win Rate | 36% | 56% | 44% | 39% | 75% | 24% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RIGL Max Drawdown | -52% | -81% | -64% | -51% | -36% | -46% | |
| Peers Max Drawdown | -44% | -50% | -58% | -58% | -44% | -58% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, EDVA, ETRA, GOSS, HYFT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/30/2026 (YTD)
How Low Can It Go
| Event | RIGL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.1% | -18.8% |
| % Gain to Breakeven | 26.8% | 23.1% |
| Time to Breakeven | 41 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.4% | -9.5% |
| % Gain to Breakeven | 73.7% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.9% | -6.7% |
| % Gain to Breakeven | 44.6% | 7.1% |
| Time to Breakeven | 20 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -75.4% | -24.5% |
| % Gain to Breakeven | 307.2% | 32.4% |
| Time to Breakeven | 887 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.0% | -33.7% |
| % Gain to Breakeven | 81.9% | 50.9% |
| Time to Breakeven | 118 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -35.2% | -19.2% |
| % Gain to Breakeven | 54.3% | 23.8% |
| Time to Breakeven | 568 days | 105 days |
In The Past
Rigel Pharmaceuticals's stock fell -21.1% during the 2025 US Tariff Shock. Such a loss loss requires a 26.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RIGL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -21.1% | -18.8% |
| % Gain to Breakeven | 26.8% | 23.1% |
| Time to Breakeven | 41 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.4% | -9.5% |
| % Gain to Breakeven | 73.7% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.9% | -6.7% |
| % Gain to Breakeven | 44.6% | 7.1% |
| Time to Breakeven | 20 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -75.4% | -24.5% |
| % Gain to Breakeven | 307.2% | 32.4% |
| Time to Breakeven | 887 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.0% | -33.7% |
| % Gain to Breakeven | 81.9% | 50.9% |
| Time to Breakeven | 118 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -35.2% | -19.2% |
| % Gain to Breakeven | 54.3% | 23.8% |
| Time to Breakeven | 568 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -47.0% | -3.7% |
| % Gain to Breakeven | 88.8% | 3.9% |
| Time to Breakeven | 252 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -35.8% | -12.2% |
| % Gain to Breakeven | 55.7% | 13.9% |
| Time to Breakeven | 141 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -35.4% | -6.8% |
| % Gain to Breakeven | 54.8% | 7.3% |
| Time to Breakeven | 99 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -51.0% | -0.2% |
| % Gain to Breakeven | 104.3% | 0.2% |
| Time to Breakeven | 492 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -30.9% | -17.9% |
| % Gain to Breakeven | 44.7% | 21.8% |
| Time to Breakeven | 175 days | 123 days |
In The Past
Rigel Pharmaceuticals's stock fell -21.1% during the 2025 US Tariff Shock. Such a loss loss requires a 26.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals, Inc. (RIGL) is a biotechnology company dedicated to discovering and developing small molecule drugs. The company focuses on addressing unmet medical needs in various therapeutic areas, including hematologic disorders, cancer, and rare immune diseases. Based in South San Francisco, California, Rigel aims to bring innovative treatments to patients grappling with these complex conditions.
Rigel's primary commercial product is Tavalisse (fostamatinib), an oral spleen tyrosine kinase inhibitor approved for treating adult patients with chronic immune thrombocytopenia, a rare blood disorder. Beyond Tavalisse, Rigel boasts a robust pipeline with several drug candidates in various stages of clinical development. Fostamatinib is also undergoing Phase III clinical trials for warm autoimmune hemolytic anemia and COVID-19. Other notable pipeline assets include R289, an IL-1R/IRAK1/4 inhibitor in Phase I for autoimmune, inflammatory, and hematology-oncology diseases, and R552, a RIPK1 inhibitor which has completed Phase I for autoimmune and inflammatory diseases.
The company's business model combines internal drug development with strategic collaborations. Rigel has established significant partnerships with larger pharmaceutical companies like AstraZeneca, BerGenBio, Daiichi Sankyo, Kissei Pharmaceutical, and Eli Lilly and Company. These collaborations are crucial for co-developing, licensing, and commercializing its drug candidates, expanding Rigel's reach into broader markets and accelerating the development of potential new therapies for a wide range of patients globally.
AI Analysis | Feedback
Here are 1-3 brief analogies for Rigel Pharmaceuticals (RIGL):
- Like a Vertex Pharmaceuticals for rare blood and immune diseases.
- A Gilead Sciences specializing in small molecule drugs for immune and blood disorders.
AI Analysis | Feedback
- Tavalisse: An oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
- Fostamatinib: A drug in phase III clinical trials for warm autoimmune hemolytic anemia and for the treatment of COVID-19.
- R289: An oral interleukin receptor associated kinase 1/4 inhibitor in phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases.
- R552: A receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trials for autoimmune and inflammatory diseases.
AI Analysis | Feedback
Rigel Pharmaceuticals, Inc. (RIGL) primarily sells its intellectual property and rights to its drug candidates to other pharmaceutical and biotechnology companies through various licensing, research, and collaboration agreements. It also sells its commercialized product, Tavalisse, to the pharmaceutical supply chain (e.g., wholesalers, distributors, specialty pharmacies).
Based on the provided description, the major identifiable customers or partners that provide revenue to Rigel Pharmaceuticals through licensing, collaboration, and research agreements include:
- AstraZeneca AB (Symbol: AZN)
- BerGenBio AS (Symbol: BGBIO.OL)
- Daiichi Sankyo (Symbol: DSNKY)
- Kissei Pharmaceutical Co., Ltd. (Symbol: KSPHF)
- Eli Lilly and Company (Symbol: LLY)
AI Analysis | Feedback
AI Analysis | Feedback
Raul R. Rodriguez, President and Chief Executive Officer
Raul R. Rodriguez joined Rigel Pharmaceuticals in April 2000, progressing through various business development and operational roles before being appointed President and Chief Executive Officer in November 2014. Earlier in his career, Mr. Rodriguez served as Chief Operating Officer of Ontogeny, an executive officer at Sense Technologies, and a director at Scios. He also held various positions at Searle Pharmaceuticals. He holds an MBA from Stanford University and an MPH from the University of Illinois.
Dean Schorno, C.P.A., Executive Vice President and Chief Financial Officer
Dean Schorno was appointed Executive Vice President and Chief Financial Officer in May 2018. Before joining Rigel, Mr. Schorno served as CFO of 23andMe, Inc. from 2015. His prior experience includes CFO roles at Adaptive Biotechnologies and Genomic Health, where he managed financial operations during periods of significant business and commercial growth, including financing and commercial transactions. Earlier in his career, he founded and led a CPA and consulting firm. Mr. Schorno is a Certified Public Accountant.
David A. Santos, Executive Vice President and Chief Commercial Officer
David A. Santos became Executive Vice President and Chief Commercial Officer in August 2020. He joined Rigel from Jazz Pharmaceuticals, where he was the Hematology/Oncology Business Unit Head, responsible for leading US commercialization of the oncology portfolio and overseeing three successful product launches. Previously, Mr. Santos held roles as Vice President of Sales and Marketing for Medivation (now Pfizer) and Vice President, Kinase Inhibitor Franchise for Onyx (now Amgen). He also spent nearly nine years at Genentech, Inc. (now a member of the Roche Group), where he held key commercial leadership positions for brands such as Avastin, Herceptin, and Tarceva.
Lisa Rojkjaer, M.D., Executive Vice President and Chief Medical Officer
Dr. Lisa Rojkjaer was appointed Executive Vice President and Chief Medical Officer in March 2024. She brings over 20 years of experience in clinical development, regulatory affairs, and medical affairs, with a specialization in hematology and oncology. Prior to Rigel, Dr. Rojkjaer served as Chief Medical Officer of Sangamo Therapeutics. Her previous roles also include Chief Medical Officer at Viracta Therapeutics and Nordic Nanovector, and Global Clinical Program Head at Novartis Pharmaceuticals.
Raymond J. Furey, Executive Vice President, General Counsel and Corporate Secretary
Raymond J. Furey was appointed Executive Vice President, General Counsel and Corporate Secretary in December 2022. Before joining Rigel, Mr. Furey was Senior Vice President, Chief Compliance Officer, and Interim General Counsel at Turning Point Pharmaceutics. He also previously served as Chief Operating Officer at Ara Pharmaceuticals. Earlier in his career, Mr. Furey held positions at OSI Pharmaceuticals and Genentech.
AI Analysis | Feedback
Key Risks to Rigel Pharmaceuticals (RIGL)
Clinical Trial and Regulatory Approval Risk: Rigel Pharmaceuticals' future growth and financial performance are heavily dependent on the successful completion of clinical trials and subsequent regulatory approvals for its pipeline candidates. Most notably, Fostamatinib is currently in multiple Phase III clinical trials for indications such as warm autoimmune hemolytic anemia and COVID-19. Any failure to achieve positive results in these trials, or an inability to obtain regulatory approval, would significantly hinder the company's ability to bring new products to market and generate revenue.
Commercialization and Market Adoption Risk for Tavalisse and Future Products: While Tavalisse is an approved product, its ongoing commercial success and market penetration are crucial for the company's current revenue. Similarly, should pipeline candidates like Fostamatinib gain regulatory approval, their commercial success will depend on factors such as market acceptance, physician adoption, competitive landscape, pricing, and reimbursement. Failure to achieve significant market uptake for Tavalisse or future approved products would negatively impact revenue and profitability.
Reliance on Collaborative Partnerships: Rigel Pharmaceuticals has entered into numerous research, license, and strategic collaboration agreements with other pharmaceutical companies, including AstraZeneca, BerGenBio, Daiichi Sankyo, Kissei Pharmaceutical, and Eli Lilly and Company. The progress and potential success of several of its pipeline assets (e.g., R256, AXL inhibitors, murine double minute 2 inhibitors, R552) are reliant on these partnerships. Any disputes, termination of agreements, or insufficient commitment from partners could delay or halt the development and commercialization of these programs, impacting Rigel's long-term prospects.
AI Analysis | Feedback
AI Analysis | Feedback
Rigel Pharmaceuticals (RIGL) operates in therapeutic areas with significant addressable markets for its main products.
For Tavalisse (fostamatinib), which is approved for chronic immune thrombocytopenia (ITP), the global market size for Immune Thrombocytopenia (ITP) treatment was valued at approximately USD 3.14 billion in 2024, with projections to reach around USD 4.53 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.4%. Another estimate places the global ITP market size at USD 3.57 billion in 2025, expected to exceed USD 4.53 billion by 2035, with a CAGR of over 2.4% during the period of 2026-2035. The U.S. market alone for Immune Thrombocytopenia exceeded USD 1.87 billion in 2023.
For Fostamatinib, which is in clinical trials for warm autoimmune hemolytic anemia (wAIHA), the global warm autoimmune hemolytic anemia (wAIHA) treatment market was valued at USD 430 million in 2024 and is projected to grow to USD 680 million by 2032, exhibiting a CAGR of 5.8%. Other estimates indicate the global wAIHA treatment sector to be valued at USD 767.53 million in 2025, with a forecast to reach USD 1.92 billion by 2035 at a CAGR of 9.6%. Another report estimated the global market to be USD 4.98 billion in 2025, growing to USD 7.24 billion by 2032, with a CAGR of 5.5%. The U.S. market size for wAIHA treatment was estimated at USD 198 million in 2024.
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- Rigel Pharmaceuticals' shares outstanding increased from 0.017 billion in Q1 2021 to 0.019 billion in Q3 2025.
- The number of shares outstanding increased by 6.52% in one year.
- A reverse stock split with a ratio of 1:10 occurred on June 27, 2024.
Inbound Investments
- Rigel Pharmaceuticals has strategic development collaborations and license agreements with various partners, including AstraZeneca AB, BerGenBio AS, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., and Eli Lilly and Company. These agreements often involve upfront and milestone payments to Rigel.
Capital Expenditures
- Rigel Pharmaceuticals reported capital expenditures of $73K in Q4 2022.
- Capital expenditures were -$38K in the last 12 months, as of the current time (March 2026), suggesting very low capital spending or net proceeds from asset disposals.
Peer Outperformance in Biotechnology
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | 37.3% | 3.0x | 62.5% | 543.5% | 52.7% | — |
| TNGX | Tango Therapeutics | 34.9% | -27.5x | 180.1% | 176.7% | 76.9% | +24pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 10.9% | 56.8% | 98.5% | CAH 480% · MCK 390% · COR 186% |
| Health Care Services | 20 | 33.8% | 44.0% | 12.4% | HIMS 255% · RDNT 136% · DGX 89% |
| Managed Health Care | 8 | 34.4% | -1.2% | -3.6% | OSCR 76% · HQY 55% · ELV 4% |
| Health Care Facilities | 25 | 12.1% | 18.2% | -5.4% | THC 281% · NHC 236% · EHC 182% |
| Health Care Equipment | 50 | 0.7% | 10.2% | -17.8% | GKOS 420% · UFPT 360% · PLSE 148% |
| Pharmaceuticals | 61 | -15.0% | 9.2% | -34.9% | LQDA 1102% · KNSA 788% · LLY 482% |
| Health Care Supplies | 11 | 15.5% | 2.3% | -39.9% | LNTH 329% · HAE 74% · MMSI 28% |
| Life Sciences Tools & Services | 107 | -8.1% | -1.9% | -66.4% | NTRA 262% · AXGN 225% · MEDP 188% |
| Biotechnology ← | 363 | -25.0% | -26.2% | -81.1% | DNTH 1187% · ELVN 1129% · TRVI 1054% |
| Health Care Technology | 21 | -23.8% | -48.9% | -82.4% | VEEV -1% · DOCS -53% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Rigel Pharmaceuticals Earnings Notes | 12/16/2025 | |
| How Low Can Rigel Pharmaceuticals Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.23 |
| Mkt Cap | 0.9 |
| Rev LTM | 277 |
| Op Inc LTM | 87 |
| FCF LTM | 79 |
| FCF 3Y Avg | 44 |
| CFO LTM | 79 |
| CFO 3Y Avg | 44 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.8% |
| Rev Chg Q | -5.1% |
| QoQ Delta Rev Chg LTM | 0.0% |
| Op Inc Chg LTM | -16.8% |
| Op Inc Chg 3Y Avg | 438.6% |
| Op Mgn LTM | 34.7% |
| Op Mgn 3Y Avg | 22.5% |
| QoQ Delta Op Mgn LTM | -5.2% |
| CFO/Rev LTM | 31.4% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 29.4% |
| FCF/Rev 3Y Avg | 15.1% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA219835 | VEPPANU | vepdegestrant | tablet | 5012026 | 25.2% | 74.5% | 74.5% | 74.5% | 74.5% |
| NDA215814 | REZLIDHIA | olutasidenib | capsule | 12012022 | 136.8% | 104.6% | 59.3% | 303.6% | 650.0% |
| NDA213721 | GAVRETO | pralsetinib | capsule | 9042020 | 33.3% | 66.2% | 75.3% | -38.1% | 122.1% |
| NDA209299 | TAVALISSE | fostamatinib disodium | tablet | 4172018 | -31.1% | -22.4% | -43.6% | -60.3% | 24.8% |
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA219835 | VEPPANU | vepdegestrant | tablet | 5012026 | 25.2% | 74.5% | 74.5% | 74.5% | 74.5% |
| NDA215814 | REZLIDHIA | olutasidenib | capsule | 12012022 | 136.8% | 104.6% | 59.3% | 303.6% | 650.0% |
| NDA213721 | GAVRETO | pralsetinib | capsule | 9042020 | 33.3% | 66.2% | 75.3% | -38.1% | 122.1% |
| NDA209299 | TAVALISSE | fostamatinib disodium | tablet | 4172018 | -31.1% | -22.4% | -43.6% | -60.3% | 24.8% |
Clinical Pipeline
| Drug Candidate | Indication | Phase 3 Trials | Est. Primary Completion |
|---|---|---|---|
| Fostamatinib disodium (R788) | Warm Antibody Autoimmune Hemolytic Anemia | 1 | Apr 2024 |
Price Behavior
| Market Price | $51.31 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 11/29/2000 | |
| Distance from 52W High | -0.3% | |
| 50 Days | 200 Days | |
| DMA Price | $47.69 | $37.15 |
| DMA Trend | up | up |
| Distance from DMA | 7.6% | 38.1% |
| 3M | 1YR | |
| Volatility | 38.3% | 62.9% |
| Downside Capture | 17.38 | 64.93 |
| Upside Capture | 192.78 | 121.49 |
| Correlation (S&P 500) | 27.2% | 17.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.81 | 0.77 | 0.93 | 0.49 | 0.88 | 1.20 |
| Up Beta | 3.08 | 0.30 | 0.28 | -0.25 | 0.45 | 0.83 |
| Down Beta | 0.50 | 0.55 | 1.18 | 1.22 | 0.86 | 1.06 |
| Up Capture | 150% | 137% | 196% | 112% | 138% | 676% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 13 | 24 | 36 | 71 | 129 | 376 |
| Down Capture | 36% | 39% | -6% | -40% | 82% | 106% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 9 | 19 | 28 | 55 | 121 | 363 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | 74.9% | 62.9% | 1.11 | - |
| Sector ETF (XLV) | 30.2% | 16.4% | 1.41 | 34.2% |
| Equity (SPY) | 10.9% | 12.8% | 0.52 | 16.7% |
| Gold (GLD) | -2.0% | 28.6% | -0.08 | 9.8% |
| Commodities (DBC) | 48.2% | 20.6% | 1.79 | -12.9% |
| Real Estate (VNQ) | 10.2% | 13.7% | 0.45 | 15.3% |
| Bitcoin (BTCUSD) | -30.0% | 43.5% | -0.70 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | 9.4% | 85.3% | 0.50 | - |
| Sector ETF (XLV) | 8.7% | 15.3% | 0.37 | 23.6% |
| Equity (SPY) | 12.2% | 17.1% | 0.53 | 25.4% |
| Gold (GLD) | 16.2% | 19.0% | 0.68 | 3.8% |
| Commodities (DBC) | 9.2% | 19.5% | 0.35 | -0.4% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 25.1% |
| Bitcoin (BTCUSD) | 4.9% | 51.6% | 0.28 | 14.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | 6.4% | 80.7% | 0.43 | - |
| Sector ETF (XLV) | 12.0% | 16.8% | 0.59 | 26.4% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 28.2% |
| Gold (GLD) | 11.4% | 16.5% | 0.56 | 2.9% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 6.4% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.21 | 23.3% |
| Bitcoin (BTCUSD) | 61.8% | 66.2% | 1.02 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/4/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 4.6% | 8.6% | 27.7% |
| 5/5/2026 | -5.1% | 4.6% | 7.7% |
| 3/3/2026 | -10.3% | -13.9% | -16.7% |
| 1/12/2026 | -2.2% | -8.2% | -15.2% |
| 11/4/2025 | 33.4% | 33.7% | 72.4% |
| 8/5/2025 | 23.0% | 42.4% | 65.6% |
| 5/6/2025 | 1.2% | 0.2% | 14.8% |
| 3/4/2025 | -8.1% | -11.7% | -17.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 18 | 17 | 19 |
| # Negative | 12 | 13 | 11 |
| Median Positive | 6.1% | 9.5% | 27.7% |
| Median Negative | -4.7% | -8.7% | -17.5% |
| Max Positive | 42.9% | 77.8% | 72.4% |
| Max Negative | -16.6% | -20.4% | -33.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | 4.6% | 8.6% | 27.7% |
| 5/5/2026 | -5.1% | 4.6% | 7.7% |
| 3/3/2026 | -10.3% | -13.9% | -16.7% |
| 1/12/2026 | -2.2% | -8.2% | -15.2% |
| 11/4/2025 | 33.4% | 33.7% | 72.4% |
| 8/5/2025 | 23.0% | 42.4% | 65.6% |
| 5/6/2025 | 1.2% | 0.2% | 14.8% |
| 3/4/2025 | -8.1% | -11.7% | -17.5% |
| 1/13/2025 | 5.3% | 23.9% | 28.2% |
| 11/7/2024 | 42.9% | 77.8% | 50.0% |
| 8/6/2024 | 5.8% | 35.8% | 43.7% |
| 5/7/2024 | -16.6% | -20.4% | -19.4% |
| 3/5/2024 | 5.4% | 0.7% | -12.8% |
| 1/8/2024 | 7.2% | -3.6% | -11.6% |
| 11/7/2023 | 2.2% | -2.3% | 31.0% |
| 8/1/2023 | -3.0% | -12.0% | -8.3% |
| 5/2/2023 | 0.9% | 1.8% | 22.8% |
| 3/7/2023 | 21.8% | 9.5% | -19.0% |
| 1/9/2023 | 12.8% | 41.6% | 34.4% |
| 11/3/2022 | 2.0% | -0.9% | 30.9% |
| 8/2/2022 | 8.5% | 4.6% | 9.2% |
| 5/3/2022 | 6.5% | -16.5% | -33.1% |
| 3/1/2022 | 21.1% | 24.7% | 19.9% |
| 1/10/2022 | -0.8% | -4.0% | 1.2% |
| 11/2/2021 | -2.5% | -8.7% | -26.9% |
| 8/3/2021 | -1.3% | 3.2% | 8.7% |
| 5/5/2021 | -6.1% | 6.3% | 14.7% |
| 3/2/2021 | -11.0% | -11.3% | -20.6% |
| 1/11/2021 | 4.7% | 10.2% | 31.9% |
| 11/5/2020 | -4.4% | -2.6% | 10.2% |
| SUMMARY STATS | |||
| # Positive | 18 | 17 | 19 |
| # Negative | 12 | 13 | 11 |
| Median Positive | 6.1% | 9.5% | 27.7% |
| Median Negative | -4.7% | -8.7% | -17.5% |
| Max Positive | 42.9% | 77.8% | 72.4% |
| Max Negative | -16.6% | -20.4% | -33.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/04/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/04/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/03/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/02/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 05/05/2020 | 10-Q |
| 12/31/2019 | 02/27/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
Recent Forward Guidance
Updated 10/26/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenues | Reported | 285.00 Mil | 290.00 Mil | 295.00 Mil | 2.7% | Raised | Guidance: 282.50 Mil for 2026 | |
| 2026 Net Product Sales | Reported | 255.00 Mil | 260.00 Mil | 265.00 Mil | 0 | Affirmed | Guidance: 260.00 Mil for 2026 | |
| 2026 Contract Revenues | Reported | 30.00 Mil | 33.3% | Raised | Guidance: 22.50 Mil for 2026 | |||
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 275.00 Mil | 282.50 Mil | 290.00 Mil | Affirmed | Guidance: 282.50 Mil for 2026 | ||
| 2026 Net Product Sales | Reported | 255.00 Mil | 260.00 Mil | 265.00 Mil | Affirmed | Guidance: 260.00 Mil for 2026 | ||
| 2026 Contract Revenues | Reported | 20.00 Mil | 22.50 Mil | 25.00 Mil | Affirmed | Guidance: 22.50 Mil for 2026 | ||
Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 275.00 Mil | 282.50 Mil | 290.00 Mil | 0 | Affirmed | Guidance: 282.50 Mil for 2026 | |
| 2026 Net Product Sales | Reported | 255.00 Mil | 260.00 Mil | 265.00 Mil | 0 | Affirmed | Guidance: 260.00 Mil for 2026 | |
| 2026 Contract Revenues | Reported | 20.00 Mil | 22.50 Mil | 25.00 Mil | 0 | Affirmed | Guidance: 22.50 Mil for 2026 | |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.